Literature DB >> 25503331

The Innovative Medicines Initiative: an engine for regulatory science.

Michel Goldman1, Nathalie Seigneuret1, Hans-Georg Eichler2.   

Abstract

Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and the lessons learned.

Mesh：

Year:  2014        PMID： 25503331     DOI： 10.1038/nrd4520

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  14 in total

1.  Benchmarking the scientific output of the Innovative Medicines Initiative.

Authors:  Magda Gunn; Mark Lim; Didi Cross; Michel Goldman
Journal:  Nat Biotechnol       Date:  2015-08       Impact factor: 54.908

Review 2.  Ethics codes and use of new and innovative drugs.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  Br J Clin Pharmacol       Date:  2019-01-04       Impact factor: 4.335

Review 3.  The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Authors:  Donald A Berry
Journal:  Mol Oncol       Date:  2015-03-11       Impact factor: 6.603

Review 4.  A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan.

Authors:  Tetsuya Tanimoto
Journal:  Drug Des Devel Ther       Date:  2015-03-31       Impact factor: 4.162

5.  Combined integrated protocol/basket trial design for a first-in-human trial.

Authors:  Ulla Derhaschnig; Jim Gilbert; Ulrich Jäger; Georg Böhmig; Georg Stingl; Bernd Jilma
Journal:  Orphanet J Rare Dis       Date:  2016-10-04       Impact factor: 4.123

Review 6.  Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Authors:  Remco L A de Vrueh; Daan J A Crommelin
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

7.  Timelines of translational science: From technology initiation to FDA approval.

Authors:  Laura M McNamee; Michael Jay Walsh; Fred D Ledley
Journal:  PLoS One       Date:  2017-05-08       Impact factor: 3.240

8.  Advancing regulatory science, advancing regulatory practice.

Authors:  Xavier Kurz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-02-21       Impact factor: 2.890

9.  Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

Authors:  Xavier Kurz; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-01-11       Impact factor: 2.890

Review 10.  Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Authors:  Alexander Schuhmacher; Oliver Gassmann; Nigel McCracken; Markus Hinder
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.